Bayer's new drugs are bringing home the bacon. The German drugmaker raised its 2015 forecast for 5 key products to €2.5 billion ($3.3 billion)--and confirmed previous promises that those drugs would surpass €5.5 billion by 2020.
Bayer's new cancer drug Stivarga has already added a notch to its belt. Cleared by the FDA last year to treat colorectal cancer, the drug is now approved as a treatment for a rare form of gastric cancer, gastrointestinal stromal tumors.
Embarrassed by the ads for erectile dysfunction drugs that pop up at the most inopportune moments? A new study found that the television commercials are indeed airing at family-viewing times--contrary to drugmakers' express promises to refrain.
In-licensed from Norway's Algeta, Alpharadin is one of the pharma company's top late-stage prospects, following a string of regulatory wins on the development front.
Europe's pharma community is revving up a drug discovery engine. A new effort involving 30 partners--including Bayer, Johnson & Johnson's Janssen and 5 other large pharmas--has launched to spark discovery of new treatments, using a crowdsourcing and open-innovation approach.
Bayer has raced to the FDA with its application for riociguat, a promising candidate for pulmonary hypertension and a key player in the pharma giant's plans for a blockbuster year in 2013 as it sets the stage for a high-profile market battle with two big competitors.
Seven major European drugmakers joined with other pharma companies, academics and other collaborators in a €196 million ($262.6 million) project to share and screen hundreds of thousands of compounds. Report
Europe's pharma community is revving up a drug-discovery engine. A new effort involving 30 partners--including Bayer, Johnson & Johnson's Janssen and 5 other large pharmas--has launched to spark discovery of new treatments, using a crowd-sourcing and open innovation approach.
What would top Xarelto for Bayer and Johnson & Johnson? Xarelto with an easy antidote.
France's drug regulators last year faced scathing criticism for dragging their feet when it came to the dangers of off-label use of diabetes drug Mediator. Now faced with consumer fears over deaths tied to off-label use of Bayer acne drug, Diane-35, they are acting with dispatch.